They work by blocking pain signals to the brain or interfering with the brain's interpretation of those signals. Analgesics are broadly categorized as being either non-opioid (non-narcotic) or opioid ...

Innocan has initiated regulatory submissions in support of advancing LPT-CBD into human clinical trials. This progress marks ...

Use of the investigational non-opioid analgesic resiniferatoxin appeared to improve pain control in patients with advanced cancer who had intractable pain, though all patients experienced adverse ...

UT Health San Antonio Multispecialty and Research Hospital is the first hospital in Texas to approve a non-narcotic ...

Non-Opioid Analgesic Development Programs". Innocan's proprietary LPT-CBD platform is uniquely positioned to align with this regulatory focus. LPT-CBD is an innovative injectable liposomal drug ...

Over 200 adverse events were reported with a single injection of resiniferatoxin in 19 patients with refractory cancer pain. At least one adverse event occurred in all patients. Resiniferatoxin ...